Towards New Therapies for Parkinson's Disease / / edited by David I Finkelstein.
Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinso...
Saved in:
| TeilnehmendeR: | |
|---|---|
| Place / Publishing House: | Croatia : : IntechOpen,, 2011. |
| Year of Publication: | 2011 |
| Language: | English |
| Physical Description: | 1 online resource (410 pages) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993547431304498 |
|---|---|
| ctrlnum |
(CKB)3230000000077137 (NjHacI)993230000000077137 (oapen)https://directory.doabooks.org/handle/20.500.12854/65253 (EXLCZ)993230000000077137 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Finkelstein, David I. edt Towards New Therapies for Parkinson's Disease / edited by David I Finkelstein. IntechOpen 2011 Croatia : IntechOpen, 2011. 1 online resource (410 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies. English Psychology. Physiological & neuro-psychology, biopsychology 953-307-463-9 Finkelstein, David I, editor. |
| language |
English |
| format |
eBook |
| author2 |
Finkelstein, David I, |
| author_facet |
Finkelstein, David I, |
| author2_variant |
d i f di dif d i f di dif |
| author2_role |
TeilnehmendeR |
| title |
Towards New Therapies for Parkinson's Disease / |
| spellingShingle |
Towards New Therapies for Parkinson's Disease / |
| title_full |
Towards New Therapies for Parkinson's Disease / edited by David I Finkelstein. |
| title_fullStr |
Towards New Therapies for Parkinson's Disease / edited by David I Finkelstein. |
| title_full_unstemmed |
Towards New Therapies for Parkinson's Disease / edited by David I Finkelstein. |
| title_auth |
Towards New Therapies for Parkinson's Disease / |
| title_new |
Towards New Therapies for Parkinson's Disease / |
| title_sort |
towards new therapies for parkinson's disease / |
| publisher |
IntechOpen IntechOpen, |
| publishDate |
2011 |
| physical |
1 online resource (410 pages) |
| isbn |
953-51-6545-3 953-307-463-9 |
| callnumber-first |
R - Medicine |
| callnumber-subject |
R - General Medicine |
| callnumber-label |
R742 |
| callnumber-sort |
R 3742.5 T693 42011 |
| illustrated |
Not Illustrated |
| dewey-hundreds |
100 - Philosophy & psychology |
| dewey-tens |
150 - Psychology |
| dewey-ones |
150 - Psychology |
| dewey-full |
150 |
| dewey-sort |
3150 |
| dewey-raw |
150 |
| dewey-search |
150 |
| work_keys_str_mv |
AT finkelsteindavidi towardsnewtherapiesforparkinsonsdisease |
| status_str |
n |
| ids_txt_mv |
(CKB)3230000000077137 (NjHacI)993230000000077137 (oapen)https://directory.doabooks.org/handle/20.500.12854/65253 (EXLCZ)993230000000077137 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Towards New Therapies for Parkinson's Disease / |
| author2_original_writing_str_mv |
noLinkedField |
| _version_ |
1787551700169523201 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00885nam a2200277 i 4500</leader><controlfield tag="001">993547431304498</controlfield><controlfield tag="005">20221010201200.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">221010s2011 ci o 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">953-51-6545-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3230000000077137</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)993230000000077137</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/65253</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993230000000077137</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">R742.5</subfield><subfield code="b">.T693 2011</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Finkelstein, David I.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Towards New Therapies for Parkinson's Disease /</subfield><subfield code="c">edited by David I Finkelstein.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">IntechOpen</subfield><subfield code="c">2011</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Croatia :</subfield><subfield code="b">IntechOpen,</subfield><subfield code="c">2011.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (410 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Psychology.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Physiological & neuro-psychology, biopsychology</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">953-307-463-9</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Finkelstein, David I,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-02-22 19:44:36 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2012-12-09 08:17:33 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338571940004498&Force_direct=true</subfield><subfield code="Z">5338571940004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338571940004498</subfield></datafield></record></collection> |